U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07791342) titled 'A Phase I Study of 9MW4113 Injection Versus Dupixent(R)' on Aug. 11.
Brief Summary: It is a randomized, double-blinded, parallel, single-dose, Phase I comparative study to evaluate the pharmacokinetic, safety, and immunogenicity similarity between 9MW4113 and Dupixent(R) in healthy Chinese adult participants. A total of 208 healthy participants are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml 9MW4113 injection or Dupixent(R).
Study Start Date: April 22
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
BIOLOGICAL: 9MW4113 injection
"9MW4113 injection; 300mg/2.0mL;...